| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/23/2004 | US20040185049 Administering to animal an interleukin-27R/cytokine receptor (IL-27R/WSX-1) ligand to treat autoimmune diseases; antiasthmatics, antiallergens, and antiinflammatory agents; diabetes |
| 09/23/2004 | US20040185048 Modulation of IL-2- and IL-15-mediated T cell responses |
| 09/23/2004 | US20040185036 treatment of platelets with certain sugar molecules, which is believed to lead to glycation of the exposed beta G1cNAc residues on GP1b alpha reduced platelet clearance, phagocytosis, increased circulation time, and increased platelet storage time |
| 09/23/2004 | US20040185032 enhanced development of prebiotic gastrointestinal ecology in patients with co-morbid diseases which exhibit problems secondary to impaired gastrointestinal health |
| 09/23/2004 | US20040185030 Methods and materials for treating inflammatory diseases |
| 09/23/2004 | US20040185029 use carbonyldiimidazole, or thiocarbonyldiimidazole, or thionyl chloride-pyridine complex, or other similar reagents to condense salicyclic acid itself into a polymer which is the polyester polysalicyclic acid |
| 09/23/2004 | US20040185014 comprises chamomile, lemon balm, passion flower, valerian, and melatonin |
| 09/23/2004 | US20040185009 Composition and device for treating periodontal diseases |
| 09/23/2004 | US20040185008 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 09/23/2004 | US20040185007 heating layers containing drugs such as benztropine, pergolide, ropinirole, amantadine and deprenyl on solid supports, to produce vapors, then condensing to aerosols which can be delivered by breathing; drug delivery method and devices |
| 09/23/2004 | US20040185006 Delivery of stimulants through an inhalation route |
| 09/23/2004 | US20040185005 Condensation aerosol as doage forms, is produced by heating a thin layer containing of dolasetron, granisetron or metoclopramide to form vapor, condense into an aerosol; fast producing peak plasma concentrations |
| 09/23/2004 | US20040185004 Delivery of erectile dysfunction drugs through an inhalation route |
| 09/23/2004 | US20040185003 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| 09/23/2004 | US20040185002 condensation aerosol for delivery of a drug selected from chlordiazepoxide, betahistine, clonidine, testosterone, a conjugated estrogen, an estrogen ester, estradiol, an estradiol ester, ethinyl estradiol, an ethinyl estradiol ester and hyoscyamine |
| 09/23/2004 | US20040185001 Delivery of physiologically active compounds through an inhalation route |
| 09/23/2004 | US20040185000 Delivery of antihistamines through an inhalation route |
| 09/23/2004 | US20040184999 Delivery of anti-migraine compounds through an inhalation route |
| 09/23/2004 | US20040184998 Delivery of drug esters through an inhalation route |
| 09/23/2004 | US20040184997 volatilizing a coating of drug on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of drug and condensing the heated vapor to form condensation aerosol particles |
| 09/23/2004 | US20040184996 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 09/23/2004 | US20040184992 Mousse composition |
| 09/23/2004 | DE202004010212U1 Lutein-enthaltende Zusammensetzung Lutein-containing composition |
| 09/23/2004 | DE10351648A1 Synergistic drug combination for primary prevention of cardiovascular disease, especially in high-risk patients, comprising acetylsalicylic acid, HMG-CoA and optionally antihypertensive agent |
| 09/23/2004 | DE10315022A1 Use of rutin or isorhamnetin, or plant parts or extracts containing them, to treat depression and related conditions, optionally incorporated into foods |
| 09/23/2004 | DE10311984A1 Using neutral endopeptidase-associated molecules for treatment, diagnosis, prophylaxis and monitoring of eating and metabolic disorders and dementia, also for drug development |
| 09/23/2004 | DE10310908A1 Treating pulmonary hypertension, using soluble guanylate cyclase stimulants, preferably pyrazolo-(3,4-b)-derivatives, as selective pulmonary vasodilators |
| 09/23/2004 | DE10310196A1 Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose Use of a tricyclic antidepressant to promote endocytosis |
| 09/23/2004 | DE10310145A1 New but-2-yl-1,4-benzoquinone derivatives, useful for treating viral diseases, especially human T-cell leukemia, obtained by culturing Malbranchea cinnamonea |
| 09/23/2004 | DE10307104A1 Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate Antitumor effective 2-substituted estra-1,3,5 (10) -triene-3-yl sulfamates |
| 09/23/2004 | CA2801100A1 Novel antibacterial agents |
| 09/23/2004 | CA2522818A1 Pharmaceutical preparations comprising acid-stabilised insulin |
| 09/23/2004 | CA2519107A1 Novel fused triazolones and the uses thereof |
| 09/23/2004 | CA2519061A1 Substituted aniline derivatives |
| 09/23/2004 | CA2518944A1 Inhibitors of extracellular hsp90 |
| 09/23/2004 | CA2518886A1 Method for treating mild cognitive impairment and for preventing or delaying alzheimer's disease |
| 09/23/2004 | CA2518883A1 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| 09/23/2004 | CA2518787A1 Antibody against tumor specific antigen as target |
| 09/23/2004 | CA2518780A1 Drug composition having active ingredient adhered at high concentration to spherical core |
| 09/23/2004 | CA2518763A1 Treatment and/or prevention of non-viral epithelial damage |
| 09/23/2004 | CA2518748A1 Antimicrobial agents and anticancer agents |
| 09/23/2004 | CA2518743A1 Protein kinase inhibitors |
| 09/23/2004 | CA2518584A1 7-amino- isoindolyl compounds and their pharmaceutical uses |
| 09/23/2004 | CA2518541A1 Gonadal function improving agents |
| 09/23/2004 | CA2518530A1 Use of isoquinoline derivatives for treating cancer and map kinase related diseases |
| 09/23/2004 | CA2518513A1 N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
| 09/23/2004 | CA2518409A1 Composition and method for treating inflammations by reducing c-reactive protein |
| 09/23/2004 | CA2518395A1 Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 09/23/2004 | CA2518393A1 Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid |
| 09/23/2004 | CA2518385A1 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine |
| 09/23/2004 | CA2518357A1 Method of treating cancer with azaspirane compositions |
| 09/23/2004 | CA2518216A1 Oral insulin therapies and protocol |
| 09/23/2004 | CA2518194A1 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| 09/23/2004 | CA2517845A1 Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
| 09/23/2004 | CA2517778A1 Extended transdermal contraceptive regimens |
| 09/23/2004 | CA2517728A1 S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate form ii crystalline salt |
| 09/23/2004 | CA2517723A1 S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine salicylate monohydrate crystalline salt |
| 09/23/2004 | CA2517720A1 Pyrazine compounds as transforming growth factor (tgf) inhibitors |
| 09/23/2004 | CA2517676A1 Method of treating cancer with quinolone carboxylic acid derivatives |
| 09/23/2004 | CA2517610A1 Microbicidal compositions including an ionene polymer and 2,4,4'-trichloro-2'-hydroxydiphenyl ether, and methods of using the same |
| 09/23/2004 | CA2517569A1 Indole derivatives useful for the treatment of diseases |
| 09/23/2004 | CA2517160A1 Method of treating and preventing hyperparathyroidism with vitamin d compounds |
| 09/23/2004 | CA2516338A1 Novel compositions containing fentanyl |
| 09/23/2004 | CA2515289A1 Weak base salts |
| 09/23/2004 | CA2514988A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them |
| 09/22/2004 | EP1460120A1 Anion generating material and skin treating agent using the same |
| 09/22/2004 | EP1460087A1 Methods of treating vascular disease with TNF antagonists |
| 09/22/2004 | EP1460082A1 Phospholipid esters of clofarabine derivatives |
| 09/22/2004 | EP1460077A1 Novel pyrazolopyrimidones and their use as PDE inhibitors |
| 09/22/2004 | EP1460075A1 Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives |
| 09/22/2004 | EP1460074A1 Substituted amino alkyl compounds |
| 09/22/2004 | EP1460073A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 09/22/2004 | EP1460072A1 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| 09/22/2004 | EP1460070A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 09/22/2004 | EP1460069A1 Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators |
| 09/22/2004 | EP1460067A1 Bicyclic derivative, process for producing the same, and use |
| 09/22/2004 | EP1460066A1 Piperazine compounds |
| 09/22/2004 | EP1460064A1 Indole-2-carboxamide derivatives useful as beta-2 agonists |
| 09/22/2004 | EP1460060A1 Method of obtaining novel lutein-based formulations |
| 09/22/2004 | EP1459768A2 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 09/22/2004 | EP1459765A1 6-fluorobicyclo 3.1.0 hexane derivatives |
| 09/22/2004 | EP1459764A1 Remedies for mild recognition deflict |
| 09/22/2004 | EP1459763A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 09/22/2004 | EP1459762A1 Preventives remedies for proliferative organ diseases chronic arthritic diseases hypertrophic scar or keloid |
| 09/22/2004 | EP1459761A1 A pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug |
| 09/22/2004 | EP1459760A1 Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof |
| 09/22/2004 | EP1459757A1 Immunomodulating polymers |
| 09/22/2004 | EP1459756A1 REMOVAL PROMOTERS AND INHIBITOR FOR APOPTOSIS CELLS i IN VIVO /i |
| 09/22/2004 | EP1459754A1 Preventives/remedies for cancer |
| 09/22/2004 | EP1459753A1 Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments |
| 09/22/2004 | EP1459752A2 Bisdioxopiperazine for the treatment of accidental extravasation of anthracyclines |
| 09/22/2004 | EP1459751A1 (S,S)-reboxetine for treating migraine headaches |
| 09/22/2004 | EP1459750A1 (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders |
| 09/22/2004 | EP1459749A1 (S,S)-reboxetine for treating incontinence |
| 09/22/2004 | EP1459748A1 (S,S)-reboxetine for treating peripheral neuropathy |
| 09/22/2004 | EP1459747A2 Method of inhibiting biosynthesis of Elf5A |
| 09/22/2004 | EP1459746A1 The use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals |
| 09/22/2004 | EP1459745A2 Method of inhibiting biosynthesis of elf5a |
| 09/22/2004 | EP1459744A2 Method of inhibiting biosynthesis of elf5a |
| 09/22/2004 | EP1459743A2 Agent for prophylaxis and treatment of glaucoma |